• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Fresh off first regulatory win, ImmunityBio hints at financial troubles

cafead

Administrator
Staff member
  • cafead   Sep 06, 2024 at 11:32: AM
via ImmunityBio has launched a round of layoffs amid potentially troubled financial waters. The staffing cuts come just months after the firm scored FDA approval of its first product, Anktiva (nogapendekin alfa inbakicept-pmln), to be used in combination with Bacillus Calmette-Guérin (BCG) to treat non-muscle invasive bladder cancer (NMIBC).

article source
 

<